Security Snapshot

Esperion Therapeutics, Inc. - COM (ESPR) Institutional Ownership

CUSIP: 29664W105

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

200

Shares (Excl. Options)

151,305,375

Price

$3.70

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period
Type / Class
Equity / COM
Symbol
ESPR on Nasdaq
Shares outstanding
258,506,508
Price per share
$2.17
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
151,305,375
Total reported value
$559,771,279
% of total 13F portfolios
0%
Share change
+43,445,139
Value change
+$165,257,335
Number of holders
200
Price from insider filings
$2.17
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • ESPR - Esperion Therapeutics, Inc. - COM is tracked under CUSIP 29664W105.
  • 200 institutions reported positions in Q4 2025.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 200 to 72 between Q4 2025 and Q1 2026.
  • Reported value moved from $559,771,279 to $141,402,440.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 200 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 29664W105?
CUSIP 29664W105 identifies ESPR - Esperion Therapeutics, Inc. - COM in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of Esperion Therapeutics, Inc. - COM (ESPR) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 6.1% +65% $43,206,778 +$23,857,290 15,768,897 +123% Wasatch Advisors LP 31 Mar 2026
Two Seas Capital LP 4.7% -6% $25,836,769 -$543,915 9,749,724 -2.1% Two Seas Capital LP 30 Sep 2025
BB BIOTECH AG 4.9% -2% $8,821,598 -$227,500 9,694,064 -2.5% BB Biotech AG 04 Mar 2025

As of 31 Dec 2025, 200 institutional investors reported holding 151,305,375 shares of Esperion Therapeutics, Inc. - COM (ESPR). This represents 59% of the company’s total 258,506,508 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Esperion Therapeutics, Inc. - COM (ESPR) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BlackRock, Inc. 6.8% 17,682,201 +19% 0% $65,424,144
VANGUARD GROUP INC 5.8% 14,945,454 +24% 0% $55,298,179
Two Seas Capital LP 4.6% 11,902,521 +22% 2.6% $44,039,328
WASATCH ADVISORS LP 3.7% 9,445,759 +34% 0.21% $34,949,308
D. E. Shaw & Co., Inc. 2.7% 6,903,483 +3209% 0.02% $25,542,887
ORBIMED ADVISORS LLC 2.3% 5,965,498 0.47% $22,072,343
STATE STREET CORP 2.3% 5,930,296 +32% 0% $21,942,095
GEODE CAPITAL MANAGEMENT, LLC 2.2% 5,737,651 +21% 0% $21,233,711
MARSHALL WACE, LLP 2.1% 5,471,611 +117% 0.02% $20,244,963
TWO SIGMA INVESTMENTS, LP 1.8% 4,742,082 +112% 0.03% $17,545,703
PenderFund Capital Management Ltd. 1.7% 4,391,926 -34% 2.6% $16,250,126
AIGH Capital Management LLC 1.5% 4,000,000 +33% 4.4% $14,800,000
MILLENNIUM MANAGEMENT LLC 1.5% 3,932,274 +303% 0.01% $14,549,414
Eversept Partners, LP 1.5% 3,851,133 0.8% $14,249,192
Nuveen, LLC 1.4% 3,612,113 -2.7% 0% $13,364,818
ROYCE & ASSOCIATES LP 1.4% 3,601,523 +57% 0.14% $13,325,635
MORGAN STANLEY 1.4% 3,514,227 -13% 0% $13,002,640
TWO SIGMA ADVISERS, LP 1.4% 3,505,200 +84% 0.03% $12,969,240
GOLDMAN SACHS GROUP INC 1.1% 2,848,216 +67% 0% $10,538,400
RENAISSANCE TECHNOLOGIES LLC 0.85% 2,194,600 +184% 0.01% $8,120,020
JONES FINANCIAL COMPANIES LLLP 0.81% 2,094,412 +167721% 0% $7,749,324
NORTHERN TRUST CORP 0.77% 1,995,706 +8% 0% $7,384,113
Walleye Capital LLC 0.61% 1,569,216 +392% 0.03% $5,806,099
Velan Capital Investment Management LP 0.47% 1,210,000 2.6% $4,477,000
Voleon Capital Management LP 0.45% 1,154,390 +455% 0.09% $4,271,243

Institutional Holders of Esperion Therapeutics, Inc. - COM (ESPR) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 51,614,251 $141,402,440 +$40,002,617 $2.74 72
2025 Q4 151,305,375 $559,771,279 +$165,257,335 $3.70 200
2025 Q3 107,960,329 $286,090,424 +$31,947,033 $2.65 187
2025 Q2 98,221,986 $96,659,560 -$21,194,525 $0.98 161
2025 Q1 111,244,473 $160,207,390 -$24,300,645 $1.44 183
2024 Q4 126,046,299 $277,285,420 +$4,393,183 $2.20 188
2024 Q3 128,986,677 $212,839,069 -$18,982,245 $1.65 181
2024 Q2 136,753,565 $303,582,298 +$17,706,459 $2.22 173
2024 Q1 125,253,343 $335,669,495 +$141,351,114 $2.68 147
2023 Q4 71,634,221 $214,185,830 -$13,154,422 $2.99 127
2023 Q3 77,232,361 $75,678,982 -$1,733,880 $0.98 120
2023 Q2 74,286,796 $103,280,736 -$10,483,186 $1.39 121
2023 Q1 80,929,285 $128,750,548 -$22,081,506 $1.59 161
2022 Q4 73,478,005 $457,748,937 +$39,215,603 $6.23 164
2022 Q3 62,444,882 $418,381,560 +$53,328,619 $6.70 143
2022 Q2 55,366,705 $352,132,262 +$24,287,037 $6.36 128
2022 Q1 51,922,058 $241,219,302 -$10,656,706 $4.64 121
2021 Q4 53,613,124 $268,022,905 +$97,310,967 $5.00 119
2021 Q3 24,797,305 $298,815,522 -$61,530,602 $12.05 133
2021 Q2 28,340,478 $599,385,890 -$18,947,335 $21.15 140
2021 Q1 28,702,213 $805,059,737 -$64,474,348 $28.05 151
2020 Q4 30,878,165 $802,895,778 -$34,208,444 $26.00 152
2020 Q3 31,640,175 $1,176,015,102 -$28,756,691 $37.17 165
2020 Q2 31,971,491 $1,640,380,010 +$123,898,647 $51.31 179
2020 Q1 29,570,957 $916,082,618 +$53,953,340 $31.53 157
2019 Q4 27,848,044 $1,621,473,992 +$45,891,970 $59.63 170
2019 Q3 27,027,940 $990,522,973 -$72,172,854 $36.66 145
2019 Q2 28,447,747 $1,323,221,426 +$216,701,139 $46.52 166
2019 Q1 27,588,882 $1,107,641,121 +$27,039,632 $40.15 160
2018 Q4 26,812,324 $1,233,297,022 -$65,824,574 $46.00 152
2018 Q3 28,254,155 $1,253,898,089 -$106,658,510 $44.37 151
2018 Q2 30,817,874 $1,207,760,885 +$133,006,694 $39.19 151
2018 Q1 26,467,526 $1,914,388,196 +$178,186,545 $72.33 184
2017 Q4 24,011,278 $1,580,908,389 +$28,478,384 $65.84 163
2017 Q3 24,158,062 $1,210,838,699 +$158,389,093 $50.12 150
2017 Q2 20,787,063 $962,036,441 +$142,703,625 $46.28 129
2017 Q1 17,982,623 $634,962,044 +$201,687,554 $35.31 116
2016 Q4 14,790,757 $185,178,042 +$1,997,113 $12.52 96
2016 Q3 14,434,779 $199,910,330 -$703,426 $13.85 98
2016 Q2 14,667,103 $144,916,054 -$27,764,688 $9.88 98
2016 Q1 15,788,626 $266,644,000 -$13,544,152 $16.91 104
2015 Q4 16,427,090 $365,743,034 -$11,898,095 $22.26 111
2015 Q3 16,611,937 $391,855,349 -$215,978,223 $23.59 120
2015 Q2 15,304,049 $1,251,247,346 +$182,794,461 $81.76 150
2015 Q1 12,803,656 $1,185,461,048 +$474,650,240 $92.60 139
2014 Q4 7,779,336 $314,790,098 +$168,789,584 $40.44 82
2014 Q3 3,501,400 $85,642,436 +$3,067,413 $24.46 49
2014 Q2 5,556,294 $88,004,478 +$33,701,269 $15.84 43
2014 Q1 3,430,835 $51,872,345 +$961,180 $15.12 40
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .